Minghao Dang

机构：The University of Texas MD Anderson Cancer Center, National University of Singapore, Harbin Institute of Technology · ORCID：0000-0001-7287-2877

发表论文 124 篇 · 总被引 4146 次 · h-index 19

代表论文

• PPP2R1A mutations portend improved survival after cancer immunotherapy (2025 · Nature · 被引 30)
• Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trial (2025 · Nature Communications · 被引 12)
• Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence (2025 · Nature Communications · 被引 7)
• Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targets (2025 · Cell Reports Medicine · 被引 4)
• Tumor Intrinsic METTL5 Modulates ATF4 Translation to Prevent T Cell‐Induced Ferroptosis in Ovarian Cancer (2025 · Advanced Science · 被引 3)
• Author Correction: PPP2R1A mutations portend improved survival after cancer immunotherapy (2025 · Nature · 被引 1)